The long-term durability of agarose microencapsulated islets against autoimmunity was evaluated in NOD mice. Islets were isolated from 6-8-week-old prediabetic male NOD mice and microencapsulated in 5% agarose hydrogel. Microencapsulated or nonencapsulated islets were transplanted into the omental pouch of spontaneously diabetic NOD mice. Although the diabetic NOD mice that received nonencapsulated islets experienced a temporary reversal of their hyperglycemic condition, all 10 of these mice returned to hyperglycemia within 3 weeks. In contrast, 9 of 10 mice transplanted with microencapsulated islets maintained normoglycemia for more than 100 days. Islet grafts were removed at 100, 150, 200, 300, and 400 days posttransplantation. A prompt return to hyperglycemia was observed in the mice after graft removal, indicating that the encapsulated islet grafts were responsible for maintaining euglycemia. Histological examination revealed viable islets in the capsules at all time points of graft removal. In addition, β-cells within the capsules remained well granulated as revealed by the immunohistochemical detection of insulin. No immune cells were detected inside the microcapsules and no morphological irregularities of the microcapsules were observed at any time point, suggesting that the microcapsules successfully protected the islets from cellular immunity. Sufficient vascularization was evident close to the microcapsules. Considerable numbers of islets showed central necrosis at 400 days posttransplantation, although the necrotic islets made up only a small percentage of the islet grafts. Islets with central necrosis also showed abundant insulin production throughout the entire islets, except for the necrotic part. These results demonstrate the long-term durability of agarose microcapsules against autoimmunity in a syngeneic islet transplantation model in NOD mice.
INTRODUCTION
tect the islet graft from both allogeneic rejection and recurring autoimmunity. Although previous studies have already demonstrated the ability of agarose microcapsules Graft rejection can be prevented by placing the donor tissue inside immunoisolation devices constructed of semi-to protect against rejection (9, 11, 18, 19) , there have been insufficient studies to conclusively demonstrate the pro-permeable membranes. Microcapsules keep the donor tissues separate from the recipient immune system and tection of microencapsulated islet grafts against autoimmunity. With this in mind, we previously studied the thus negate the need for systemic immune suppression. Isolated pancreatic islets transplanted for the treatment ability of agarose microcapsules to protect islets from autoimmune destruction (13). However, the question of of type 1 diabetes are subject to both allogeneic rejection and autoimmune destruction by the recipient's immune how long these microcapsules can function and maintain their shape in vivo was not assessed in our previous system. Therefore, to achieve "immunosuppressant-free islet transplantation," microcapsules are required to pro-study. Thus, the long-term durability of agarose micro-360 KOBAYASHI ET AL.
capsules in an autoimmune environment remains un-Microencapsulation clear.
Islets were microencapsulated in agarose according The most commonly used microcapsules are comto previously reported methods with minor modificaposed of alginate. Graft survival of alginate encapsutions (10). Briefly, purified islets were suspended in 0.2 lated islets is remarkably prolonged compared to that of ml of HBSS and then mixed with 5% agarose solution nonencapsulated islets, but the duration of euglycemia (Agarose-LGT, Nacalai Tesque Inc, Kyoto, Japan, 150 is unfortunately limited to periods varying from several mg agarose in 3 ml of HBSS). The agarose solution conmonths in rats (4) to 6 months in dogs (17) . Although taining the islets was emulsified by adding paraffin oil long-term graft survival of alginate microencapsulated in 37°C and then immediately solidified by manual islets was reported in NOD mice (5), others reported the shaking in an ice bath for 5 min. Agarose microcapsules limited graft survival of alginate microencapsulated iswere washed with HBSS and then cultured at 37°C overlets even in an islet isograft model (2-4,16). De Groot et night. Because a considerable number of empty capsules al.
(2) maintained that a lack of biocompatibility and hywere made during the encapsulation process, the micropoxia may be responsible for the limited graft survival of capsules containing islets were hand-picked under a mialginate microencapsulated islets. We focused on agarose croscope prior to transplantation. This encapsulation microcapsules, which possibly differ from alginate with procedure results in the formation of morphologically regard to biocompatibility, and tried to overcome the hyconsistent microcapsules. The diameter of each capsules poxia issue by transplantation into the omental pouch, with an entrapped islet ranged from 100 to 400 µm. which exhibits angiogenic potential by promoting neo-Typically, each capsule did not contain more than one vascularization in ischemic tissues. In this study, microislet. encapsulated NOD islets were transplanted into the omental pouch in NOD mice and subsequently followed Transplantation for long-term graft function, which was confirmed histo-Microencapsulated islets were transplanted into the logically at 400 days posttransplantation.
omental pouch of diabetic mice under sodium pentobar-MATERIALS AND METHODS bital anesthesia. A median abdominal incision was made Animals and the greater omentum was spread out onto wet gauze. Grafts consisting of 1500 microencapsulated islets (ap-NOD/Shi mice were purchased from Clea Japan proximately 500 µl) were placed onto the exposed omen-(Tokyo, Japan). In these animals, the cumulative incitum. Next, the omentum was folded up and attached to dence of diabetes is 23% and 80% in females and 0% the stomach using 5-0 nylon sutures to make a pouch. and 30% in males at 20 and 30 weeks of age, respec-Controls included mice that had 1500 nonencapsulated tively (data provided by Clea Japan). Diabetic female islets transplanted into the omental pouch. mice were used as recipients and young (6-8 weeks of age) nondiabetic male mice were used as islet donors.
Assessment of Graft Function Prediabetic female mice were screened weekly for diabetes by measuring the nonfasting blood glucose level Islet recipients were monitored daily for the first 2 between 0800 and 1000 h, and spontaneous diabetes was weeks posttransplantation and twice a week thereafter diagnosed when the blood glucose level in two consecufor their nonfasting blood glucose level. Diabetes recurtive measurements exceeded 20.0 mmol/L. Diabetic rence was diagnosed when the blood glucose level was NOD mice were transplanted with islets 5-10 days after greater than 11.1 mmol/L on any single measurement. onset of diabetes.
Histological Examination Islet Isolation
Donor islets were prepared using a modification (7) Omental pouches were removed at 100, 150, 200, 300, and 400 days posttransplantation from recipients of the method described by Lacy et al. (14) . Briefly, under sodium pentobarbital anesthesia, pancreata were that had maintained normoglycemia. The graft-bearing omentum was fixed in 10% buffered formalin, embed-distended with 2.5 ml of cold Hanks' balanced salt solution (HBSS) (Nissui Pharmaceutical Co. Ltd., Tokyo, ded in paraffin, and sectioned at 4.5 µm. The sections were stained with an anti-insulin antibody (Oriental Japan) containing 1.5 mg/ml of collagenase (type V; Sigma, St. Louis, MO). The distended pancreata were Yeast Co. Ltd., Osaka, Japan) using an immunoperoxidase technique and counterstained with hematoxylin and then removed and digested for 12 min at 37°C. Islets were purified by centrifugation through discontinuous eosin. The omentum was also evaluated histologically by aldehyde-fuchsin staining as previously described (15). dextran gradients.
RESULTS
duction, except for the necrotic part, as evaluated by immunohistochemistry of the entire islet ( Fig. 2E ).
Graft Function
Although diabetic NOD mice that received 1500 non-DISCUSSION encapsulated islets experienced a temporary reversal of their hyperglycemic condition within 2 days after trans-In this study, we achieved reversal of diabetes in a plantation, all of these mice returned to hyperglycemia syngeneic NOD mouse model and demonstrated the longat 12.2 ± 4.0 days (range, 6-21 days) posttransplantaterm durability of agarose microcapsules in vivo. To our tion (Table 1, Fig. 1A) . In contrast, mice that received knowledge, this is the first report to present histological 1500 microencapsulated islets experienced normoglydata for functioning microencapsulated islets at 400 days cemia for extended periods of time after transplantation posttransplantation. (Fig. 1B) . Their blood glucose level dropped from a pre-It is interesting to note that a considerable number transplantation level of 25.6 ± 3.0 mmol/L to 4.0 ± 0.9 of the microencapsulated islets had central necrosis, as mmol/L at 2 days posttransplantation. All these mice indicated by the histology. This result led us to speculate maintained normoglycemia for more than 100 days, exabout the mechanism of graft failure for microencapsucept for one mouse that returned to hyperglycemia at 65 lated islets. Microcapsules allow the passage of small days posttransplantation. Omental pouches were removed molecules such as insulin and glucose, but prevent the at 100, 150, 200, 300, and 400 days posttransplantation entry of immune cells. The exact mechanism for microfrom recipients that had maintained normoglycemia. A encapsulated islet graft failure (e.g., cytokines, nitric oxprompt return to hyperglycemia in these mice was obide, perforin, poor nutrition, or hypoxia) is currently unserved after graft removal, indicating that the encapsuknown. Based on the histological finding of central lated islet grafts were responsible for maintaining the necrosis in the islets, we speculate that chronic hypoxia euglycemia. and poor nutrition are the most likely major causes of islet cell death in microcapsules. If cytotoxic mediators, Histological Examination such as cytokines, were responsible for the graft necrosis, the islets would be damaged around the periphery Transplanted microencapsulated islets firmly adhered to the omentum. Histological examination of the graft-with the center remaining intact and viable. However, the observations in the current study reveals that the op-bearing omentum revealed viable islets in the capsules without mononuclear cellular infiltration at all time posite is in fact the case, with islets appearing necrotic in the center and remaining viable and insulin-rich points of graft removal (Fig. 2 shows the histological findings at 400 days posttransplantation). In addition, βaround the periphery. These results therefore suggest that microencapsulated islets lose function due to the cells within the capsules remained intact and well granulated, indicating the presence of insulin ( Fig. 2A-C) .
detrimental effects of chronic hypoxia and poor nutrition, because the central part of the islets probably suf-Morphological irregularities of the microcapsules were not observed. No immune cells were detected inside the fers more severe hypoxia and poorer nutrition than the periphery. microcapsules at any time point, suggesting that the microcapsules successfully protected the islets from cellu-Alginate is commonly used as the capsule material for microencapsulated islet transplantation. However, lim-lar immunity. Sufficient vascularization was evident close to the microcapsule ( Fig. 2A, C) . However, as shown in ited graft survival has been reported, even with islet isografts (2-4,16), whereas long-term graft function was Figure 2D -F, a considerable number of islets showed central necrosis at 400 days after transplantation, al-reported in NOD mice (5). In this study we achieved long-term normoglycemia with agarose microcapsules though the necrotic islets only made up a small percentage of the islet grafts. Islets with central necrosis also up to 400 days posttransplantation. Some possible reasons for the improved graft survival observed in the had intact capsules and showed sufficient insulin pro- 
